Table 4.
aBMD and BMAD During 3 Years of Gender-Affirming Hormone Treatment in Addition to GnRHa Treatment
| Transgirls | ||||||
|---|---|---|---|---|---|---|
| Early-Pubertal | Late-Pubertal | |||||
| 0 | 36 | 0 | 36 | p1 | p2 | |
| aBMD_LS g/cm2 | 0.77 (0.03) | 0.95 (0.04) | 0.83 (0.02) | 0.95 (0.03) | <0.05 | <0.05 |
| Z-score | −1.37 (0.30) | −0.82 (0.39) | −0.99 (0.19) | −1.05 (0.25) | <0.05 | n.s. |
| aBMD_hip g/cm2 | 0.87 (0.03) | 1.02 (0.04) | 0.88 (0.02) | 0.96 (0.02) | <0.05 | <0.05 |
| Z-score | −0.99 (0.23) | −0.09 (0.28) | −0.86 (0.14) | −0.70 (0.18) | <0.05 | n.s. |
| Whole body BMD g/cm2 | 0.93 (0.02) | 1.06 (0.06) | 0.96 (0.01) | 0.98 (0.04) | <0.05 | n.s. |
| Z-score | −1.67 (0.23) | −1.22 (0.28) | −1.42 (0.14) | −1.48 (0.18) | <0.05 | n.s. |
| BMAD_LS g/cm3 | 0.20 (0.08) | 0.24 (0.09) | 0.21 (0.05) | 0.24 (0.06) | <0.05 | <0.05 |
| Z-score | −1.39 (0.36) | −0.49 (0.40) | −1.29 (0.23) | −0.50 (0.25) | <0.05 | <0.05 |
| BMAD_hip g/cm3 | 0.28 (0.01) | 0.31 (0.02) | 0.27 (0.01) | 0.27 (0.01) | <0.05 | <0.05 |
| Z-score | −0.88 (0.23) | −0.35 (0.37) | −1.36 (0.20) | −1.21 (0.24) | <0.05 | <0.05 |
| Transboys | ||||||
| Early-pubertal | Late-pubertal | |||||
| 0 | 36 | 0 | 36 | p1 | p2 | |
| aBMD_LS g/cm2 | 0.82 (0.04) | 1.02 (0.07) | 0.90 (0.02) | 0.99 (0.02) | <0.05 | <0.05 |
| Z-score | −1.30 (0.43) | 0.11 (0.58) | −0.68 (0.16) | −0.26 (0.22) | <0.05 | <0.05 |
| aBMD_hip g/cm2 | 0.83 (0.04) | 1.02 (0.06) | 0.88 (0.02) | 0.96 (0.02) | <0.05 | <0.05 |
| Z-score | −0.82 (0.33) | 0.59 (0.43) | −0.50 (0.12) | 0.12 (0.16) | <0.05 | <0.05 |
| Whole body BMD g/cm2 | 0.94 (0.03) | 1.11 (0.10) | 1.02 (0.01) | 1.10 (0.03) | n.s. | <0.05 |
| Z-score | −1.06 (0.32) | 0.21(0.43) | −0.30 (0.12) | −0.05 (0.16) | <0.05 | <0.05 |
| BMAD_LS g/cm3 | 0.22(0.01) | 0.26 (0.01) | 0.24 (0.01) | 0.26 (0.01) | <0.05 | <0.05 |
| Z-score | −1.01 (0.49) | 0.12 (0.51) | −0.61 (0.18) | −0.04 (0.18) | <0.05 | <0.05 |
| BMAD_hip g/cm3 | 0.28 (0.02) | 0.32 (0.02) | 0.30 (0.01) | 0.32 (0.01) | <0.05 | n.s. |
| Z-score | −0.71 (0.37) | 0.01 (0.43) | −0.41 (0.14) | −0.10 (0.16) | <0.05 | n.s. |
aBMD and BMAD during 3 years of GnRHa plus gender-affirming hormone treatment. Values are presented as estimated marginal means ± standard error. p1 represents the P value between start and after 3 years of treatment for the early-pubertal groups. p2 represents the P value between start and after 3 years of treatment for the late-pubertal groups.
For changes per year of treatment see Fig. 2.
Abbreviations: aBMD, areal bone mineral density; BMAD, bone mineral apparent density; BMD, bone mineral density; LS, lumbar spine.